Achalasia

The Lancet

Volumn 383, Issue 9911, 2014, Pages 83-93

  Boeckxstaens, Guy E ^a   Zaninotto, Giovanni ^b   Richter, Joel E ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; NITRATE; PROTON PUMP INHIBITOR;

CARDIOESOPHAGOMYOTOMY; DYSPHAGIA; ENDOSCOPY; ESOPHAGUS ACHALASIA; ESOPHAGUS CARCINOMA; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; ESOPHAGUS MYOTOMY; ESOPHAGUS RESECTION; HUMAN; MINIMALLY INVASIVE PROCEDURE; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION; DILATATION; EARLY DIAGNOSIS; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; MANOMETRY; METHODOLOGY; MINIMALLY INVASIVE SURGERY; PRECANCER; RECURRENT DISEASE;

DILATATION; EARLY DETECTION OF CANCER; ESOPHAGEAL ACHALASIA; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; MANOMETRY; PRECANCEROUS CONDITIONS; RECURRENCE; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 84892695331     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60651-0     Document Type: Review

References (143)

1. Vantrappen G, Hellemans J, Deloof W, et al. Treatment of achalasia with pneumatic dilatations. Gut 1971; 12: 268-75.
2. Richter JE, Boeckxstaens GE. Management of achalasia: surgery or pneumatic dilation. Gut 2011; 60: 869-76.
3. Willis T. Pharmaceutice Rationalis Sive Diatribe de Medicamentorum Operationibus in Human Corpore. London, England: Hagae Comitis, 1674.
4. Boeckxstaens GE. The lower oesophageal sphincter. Neurogastroenterol Motil 2005; 17 (suppl 1): 13-21
5. Kahrilas PJ, Kishk SM, Helm JF, Dodds WJ, Harig JM, Hogan WJ. Comparison of pseudoachalasia and achalasia. Am J Med 1987; 82: 439-46.
6. Tracey JP, Traube M. Difficulties in the diagnosis of pseudoachalasia. Am J Gastroenterol 1994; 89: 2014-18.
7. de Borst JM, Wagtmans MJ, Fockens P, et al. Pseudoachalasia caused by pancreatic carcinoma. Eur J Gastroenterol Hepatol 2003; 15: 825-28.
8. Herbella FA, Aquino JL, Stefani-Nakano S, et al. Treatment of achalasia: lessons learned with Chagas' disease. Dis Esophagus 2008; 21: 461-67.
9. Pinazo MJ, Canas E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010; 33: 191-200.
10. Meneghelli UG, Peria FM, Darezzo FM, et al. Clinical, radiographic, and manometric evolution ofesophageal involvement by Chagas' disease. Dysphagia 2005; 20: 40-45.
11. Hejazi RA, Zhang D, McCallum RW. Gastroparesis, pseudoachalasia and impaired intestinal motility as paraneoplastic manifestations of small cell lung cancer. Am J Med Sci 2009; 338: 69-71.
12. Gockel HR, Schumacher J, Gockel I, et al. Achalasia: will genetic studies provide insights? Hum Genet 2010; 128: 353-64.
13. Farrukh A, DeCaestecker J, Mayberry JF. An epidemiological study of achalasia among the south Asian population of Leicester, 1986-2005. Dysphagia 2008; 23: 161-64.
14. Sadowski DC, Ackah F, Jiang B, et al. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil 2010; 22: e256-61.
15. Birgisson S, Richter JE. Achalasia in Iceland, 1952-2002: an epidemiologic study. Dig Dis Sci 2007; 52: 1855-60.
16. Gennaro N, Portale G, Gallo C, et al. Esophageal achalasia in the Veneto region: epidemiology and treatment. Epidemiology and treatment of achalasia. J Gastrointest Surg 2011; 15: 423-28.
17. Marlais M, Fishman JR, Fell JM, et al. UK incidence of achalasia: an 11-year national epidemiological study. Arch Dis Child 2011; 96: 192-94.
18. Enestvedt BK, Williams JL, Sonnenberg A. Epidemiology and practice patterns of achalasia in a large multi-centre database. Aliment Pharmacol Ther 2011; 33: 1209-14.
19. Booy JD, Takata J, Tomlinson G, et al. The prevalence of autoimmune disease in patients with esophageal achalasia. Dis Esophagus 2012; 25: 209-13.
20. Clark SB, Rice TW, Tubbs RR, et al. The nature of the myenteric infiltrate in achalasia: an immunohistochemical analysis. Am J Surg Pathol 2000; 24: 1153-58.
21. Goldblum JR, Rice TW, Richter JE. Histopathologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996; 111: 648-54.
22. Villanacci V, Annese V, Cuttitta A, et al. An immunohistochemical study of the myenteric plexus in idiopathic achalasia. J Clin Gastroenterol 2010; 44: 407-10.
23. Storch WB, Eckardt VF, Junginger T. Complement components and terminal complement complex in oesophageal smooth muscle of patients with achalasia. Cell Mol Biol (Noisy-le-grand) 2002; 48: 247-52.
24. Storch WB, Eckardt VF, Wienbeck M, et al. Autoantibodies to Auerbach's plexus in achalasia. Cell Mol Biol (Noisy-le-grand) 1995; 41: 1033-38.
25. Moses PL, Ellis LM, Anees MR, et al. Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal refl ux disease. Gut 2003; 52: 629-36.
26. Ruiz-de-Leon A, Mendoza J, Sevilla-Mantilla C, et al. Myenteric antiplexus antibodies and class II HLA in achalasia. Dig Dis Sci 2002; 47: 15-19.
27. Castagliuolo I, Brun P, Costantini M, et al. Esophageal achalasia: is the herpes simplex virus really innocent? J Gastrointest Surg 2004; 8: 24-30.
28. Facco M, Brun P, Baesso I, et al. T cells in the myenteric plexus of achalasia patients show a skewed TCR repertoire and react to HSV-1 antigens. Am J Gastroenterol 2008; 103: 1598-609.
29. Boeckxstaens GE. Achalasia: virus-induced euthanasia of neurons? Am J Gastroenterol 2008; 103: 1610-12.
30. Birgisson S, Galinski MS, Goldblum JR, et al. Achalasia is not associated with measles or known herpes and human papilloma viruses. Dig Dis Sci 1997; 42: 300-06.
31. Niwamoto H, Okamoto E, Fujimoto J, et al. Are human herpes viruses or measles virus associated with esophageal achalasia? Dig Dis Sci 1995; 40: 859-64.
32. De la Concha EG, Fernandez-Arquero M, Mendoza JL, et al. Contribution of HLA class II genes to susceptibility in achalasia. Tissue Antigens 1998; 52: 381-84.
33. Verne GN, Hahn AB, Pineau BC, et al. Association of HLA-DR and-DQ alleles with idiopathic achalasia. Gastroenterology 1999; 117: 26-31.
34. de la Concha EG, Fernandez-Arquero M, Conejero L, et al. Presence of a protective allele for achalasia on the central region of the major histocompatibility complex. Tissue Antigens 2000; 56: 149-53.
35. Paladini F, Cocco E, Cascino I, et al. Age-dependent association of idiopathic achalasia with vasoactive intestinal peptide receptor 1 gene. Neurogastroenterol Motil 2009; 21: 597-602.
36. Alahdab YO, Eren F, Giral A, et al. Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population. Neurogastroenterol Motil 2012; 24: 27-30.
37. Nunez C, Garcia-Gonzalez MA, Santiago JL, et al. Association of IL10 promoter polymorphisms with idiopathic achalasia. Hum Immunol 2011; 72: 749-52.
38. de Leon AR, de la Serna JP, Santiago JL, et al. Association between idiopathic achalasia and IL23R gene. Neurogastroenterol Motil 2010; 22: 734-38, e218.
39. Hulselmans M, Vanuytsel T, Degreef T, et al. Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol 2010; 8: 30-35.
40. Eckardt VF, Stauf B, Bernhard G. Chest pain in achalasia: patient characteristics and clinical course. Gastroenterology 1999; 116: 1300-04.
41. Fisichella PM, Raz D, Palazzo F, et al. Clinical, radiological, and manometric profile in 145 patients with untreated achalasia. World J Surg 2008; 32: 1974-79.
42. Rohof WO, Salvador R, Annese V, et al. Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology 2013; 144: 718-25.
43. Eckardt VF. Clinical presentations and complications of achalasia. Gastrointest Endosc Clin N Am 2001; 11: 281-92, vi.
44. Eckardt VF, Kohne U, Junginger T, et al. Risk factors for diagnostic delay in achalasia. Dig Dis Sci 1997; 42: 580-85
45. El-Takli I, O'Brien P, Paterson WG. Clinical diagnosis of achalasia: how reliable is the barium x-ray? Can J Gastroenterol 2006; 20: 335-37.
46. Howard PJ, Maher L, Pryde A, et al. Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh. Gut 1992; 33: 1011-15.
47. Moonen AJ, Boeckxstaens GE. Management of achalasia. Gastroenterol Clin N Am 2013; 42: 45-55.
48. Triadafilopoulos G, Boeckxstaens GE, Gullo R, et al. The Kagoshima consensus on esophageal achalasia. Dis Esophagus 2012; 25: 337-48.
49. Vaezi MF, Baker ME, Achkar E, et al. Timed barium oesophagram: better predictor of long term success after pneumatic dilation in achalasia than symptom assessment. Gut 2002; 50: 765-70.
50. de Oliveira JM, Birgisson S, Doinoff C, et al. Timed barium swallow: a simple technique for evaluating esophageal emptying in patients with achalasia. AJR Am J Roentgenol 1997; 169: 473-79.
51. Bredenoord AJ, Fox M, Kahrilas PJ, et al. Chicago classification criteria ofesophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil 2012; 24 (suppl 1): 57-65.
52. Kahrilas PJ. Esophageal motor disorders in terms of high-resolution esophageal pressure topography: what has changed? Am J Gastroenterol 2010; 105: 981-87.
53. Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 2008; 135: 1526-33.
54. Boeckxstaens G, Zaninotto G. Achalasia and esophago-gastric junction outfl ow obstruction: focus on the subtypes. Neurogastroenterol Motil 2012; 24 (suppl 1): 27-31.
55. Ghosh SK, Pandolfino JE, Rice J, et al. Impaired deglutitive EGJ relaxation in clinical esophageal manometry: a quantitative analysis of 400 patients and 75 controls. Am J Physiol Gastrointest Liver Physiol 2007; 293: G878-85.
56. Lin Z, Kahrilas PJ, Roman S, et al. Refining the criterion for an abnormal integrated relaxation pressure in esophageal pressure topography based on the pattern ofesophageal contractility using a classification and regression tree model. Neurogastroenterol Motil 2012; 24: e356-63.
57. Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 1982; 83: 963-69.
58. Bortolotti M, Labo G. Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology 1981; 80: 39-44.
59. Traube M, Dubovik S, Lange RC, et al. The role of nifedipine therapy in achalasia: results of a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1989; 84: 1259-62.
60. Triadafilopoulos G, Aaronson M, Sackel S, et al. Medical treatment ofesophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo. Dig Dis Sci 1991; 36: 260-67.
61. Wen ZH, Gardener E, Wang YP. Nitrates for achalasia. Cochrane Database Syst Rev 2004; 1: CD002299.
62. Richter JE. Achalasia-an update. J Neurogastroenterol Motil 2010; 16: 232-42.
63. Pasricha PJ, Ravich WJ, Hendrix TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 332: 774-78.
64. Annese V, Bassotti G, Coccia G, et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut 2000; 46: 597-600.
65. Leyden JE, Moss AC, MacMathuna P. Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev 2006; 4: CD005046.
66. Muehldorfer SM, Schneider TH, Hochberger J, et al. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy 1999; 31: 517-21.
67. Vaezi MF, Richter JE, Wilcox CM, et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut 1999; 44: 231-39.
68. Ghoshal UC, Chaudhuri S, Pal BB, et al. Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia. Dis Esophagus 2001; 14: 227-31.
69. Mikaeli J, Fazel A, Montazeri G, et al. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther 2001; 15: 1389-96.
70. Zhu Q, Liu J, Yang C. Clinical study on combined therapy of botulinum toxin injection and small balloon dilation in patients with esophageal achalasia. Dig Surg 2009; 26: 493-98.
71. Zaninotto G, Annese V, Costantini M, et al. Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia. Ann Surg 2004; 239: 364-70.
72. Johns Hopkins Medicine, Gastroenterology and Hepatology. Swallowing disorders: therapy. http://www.hopkins-gi.org/GDL-Disease.aspx?GDL-Cat-ID= AF793A59-B736-42CB-9E1FE79D2B9FC358& GDL-Disease-ID=0E11DE8C-7FB7-47AE-BC76- 766AC830F7BA (accessed April 30, 2013).
73. Kadakia SC, Wong RK. Graded pneumatic dilation using Rigifl ex achalasia dilators in patients with primary esophageal achalasia. Am J Gastroenterol 1993; 88: 34-38.
74. Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology 1992; 103: 1732-38.
75. Rohof WO, Lei A, Boeckxstaens GE. Esophageal stasis on a timed barium esophagogram predicts recurrent symptoms in patients with long-standing achalasia. Am J Gastroenterol 2013; 108: 49-55
76. Vela MF, Richter JE, Khandwala F, et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin Gastroenterol Hepatol 2006; 4: 580-87.
77. Richter JE. Update on the management of achalasia: balloons, surgery and drugs. Expert Rev Gastroenterol Hepatol 2008; 2: 435-45.
78. Zerbib F, Thetiot V, Richy F, et al. Repeated pneumatic dilations as long-term maintenance therapy for esophageal achalasia. Am J Gastroenterol 2006; 101: 692-97.
79. Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med 2011; 364: 1807-16.
80. O'Connor JB, Singer ME, Imperiale TF, et al. The cost-effectiveness of treatment strategies for achalasia. Dig Dis Sci 2002; 47: 1516-25.
81. Karanicolas PJ, Smith SE, Inculet RI, et al. The cost of laparoscopic myotomy versus pneumatic dilatation for esophageal achalasia. Surg Endosc 2007; 21: 1198-206.
82. Guardino JM, Vela MF, Connor JT, et al. Pneumatic dilation for the treatment of achalasia in untreated patients and patients with failed Heller myotomy. J Clin Gastroenterol 2004; 38: 855-60.
83. Katzka DA, Castell DO. Review article: an analysis of the efficacy, perforation rates and methods used in pneumatic dilation for achalasia. Aliment Pharmacol Ther 2011; 34: 832-39.
84. Vanuytsel T, Lerut T, Coosemans W, et al. Conservative management ofesophageal perforations during pneumatic dilation for idiopathic esophageal achalasia. Clin Gastroenterol Hepatol 2012; 10: 142-49
85. Metman EH, Lagasse JP, d'Alteroche L, et al. Risk factors for immediate complications after progressive pneumatic dilation for achalasia. Am J Gastroenterol 1999; 94: 1179-85.
86. Heller E. Extramukose kardioplastik beim chronischen kardiospasm mit dilatation des oesophagus. Mitt Greenzgeb Med Chir 1913; 27: 141-48.
87. Zaaijer JH. Cardiospasm in the aged. Ann Surg 1923; 77: 615-17
88. Zaninotto G, Costantini M. Laparoscopic esophageal myotomy: techniques and results. In: Yeo CJ, ed. Shackelfords surgery of the alimentary tract. Philadelphia: Elsevier-Saunders, 2013: 354-61
89. Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010; 42: 265-71.
90. Dor J, Humbert P, Paoli JM, et al. Treatment of refl ux by the so-called modified Heller-Nissen technic. Presse Med 1967; 75: 2563-65.
91. Pellegrini C, Wetter LA, Patti M, et al. Thoracoscopic esophagomyotomy. Initial experience with a new approach for the treatment of achalasia. Ann Surg 1992; 216: 291-96; discussion 296-99.
92. Campos GM, Vittinghoff E, Rabl C, et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann Surg 2009; 249: 45-57.
93. Richards WO, Torquati A, Holzman MD, et al. Heller myotomyversus Heller myotomy with Dor fundoplication for achalasia:a prospective randomized double-blind clinical trial. Ann Surg 2004; 240: 405-12; discussion 12-15.
94. Rebecchi F, Giaccone C, Farinella E, et al. Randomized controlled trial of laparoscopic Heller myotomy plus Dor fundoplication versus Nissen fundoplication for achalasia: long-term results. Ann Surg 2008; 248: 1023-30.
95. Rawlings A, Soper NJ, Oelschlager B, et al. Laparoscopic Dor versus Toupet fundoplication following Heller myotomy for achalasia: results of a multicenter, prospective, randomized-controlled trial. Surg Endosc 2012; 26: 18-26.
96. Oelschlager BK, Chang L, Pellegrini CA. Improved outcome after extended gastric myotomy for achalasia. Arch Surg 2003; 138: 490-95; discussion 495-97.
97. Perrone JM, Frisella MM, Desai KM, et al. Results of laparoscopic Heller-Toupet operation for achalasia. Surg Endosc 2004; 18: 1565-71.
98. Rossetti G, Brusciano L, Amato G, et al. A total fundoplication is not an obstacle to esophageal emptying after Heller myotomy for achalasia: results of a long-term follow up. Ann Surg 2005; 241: 614-21.
99. Torquati A, Richards WO, Holzman MD, et al. Laparoscopic myotomy for achalasia: predictors of successful outcome after 200 cases. Ann Surg 2006; 243: 587-91; discussion 91-93.
100. Schuchert MJ, Luketich JD, Landreneau RJ, et al. Minimally-invasive esophagomyotomy in 200 consecutive patients: factors infl uencing postoperative outcomes. Ann Thorac Surg 2008; 85: 1729-34.
101. Zaninotto G, Costantini M, Rizzetto C, et al. Four hundred laparoscopic myotomies for esophageal achalasia: a single centre experience. Ann Surg 2008; 248: 986-93.
102. Snyder CW, Burton RC, Brown LE, et al. Multiple preoperative endoscopic interventions are associated with worse outcomes after laparoscopic Heller myotomy for achalasia. J Gastrointest Surg 2009; 13: 2095-103.
103. Finley CJ, Kondra J, Clifton J, et al. Factors associated with postoperative symptoms after laparoscopic Heller myotomy. Ann Thorac Surg 2010; 89: 392-96.
104. Rosemurgy AS, Morton CA, Rosas M, et al. A single institution's experience with more than 500 laparoscopic Heller myotomies for achalasia. J Am Coll Surg 2010; 210: 637-45, 645-47.
105. Carter JT, Nguyen D, Roll GR, et al. Predictors of long-term outcome after laparoscopic esophagomyotomy and Dor fundoplication for achalasia. Arch Surg 2011; 146: 1024-28.
106. Costantini M, Zaninotto G, Guirroli E, et al. The laparoscopic Heller-Dor operation remains an effective treatment for esophageal achalasia at a minimum 6-year follow-up. Surg Endosc 2005; 19: 345-51
107. Chen Z, Bessell JR, Chew A, et al. Laparoscopic cardiomyotomy for achalasia: clinical outcomes beyond 5 years. J Gastrointest Surg 2010; 14: 594-600.
108. Salvador R, Costantini M, Zaninotto G, et al. The preoperativemanometric pattern predicts the outcome of surgical treatment for esophageal achalasia. J Gastrointest Surg 2010; 14: 1635-45.
109. Portale G, Costantini M, Rizzetto C, et al. Long-term outcome of laparoscopic Heller-Dor surgery for esophageal achalasia: possible detrimental role of previous endoscopic treatment. J Gastrointest Surg 2005; 9: 1332-39.
110. Zaninotto G, Costantini M, Portale G, et al. Etiology, diagnosis, and treatment of failures after laparoscopic Heller myotomy for achalasia. Ann Surg 2002; 235: 186-92.
111. Lopushinsky SR, Urbach DR. Pneumatic dilatation and surgical myotomy for achalasia. JAMA 2006; 296: 2227-33.
112. von Renteln D, Inoue H, Minami H, et al. Peroral endoscopic myotomy for the treatment of achalasia: a prospective single center study. Am J Gastroenterol 2012; 107: 411-17.
113. Swanstrom LL, Kurian A, Dunst CM, et al. Long-term outcomes of an endoscopic myotomy for achalasia: the POEM procedure. Ann Surg 2012; 256: 659-67.
114. Costamagna G, Marchese M, Familiari P, et al. Peroral endoscopic myotomy (POEM) for oesophageal achalasia: preliminary results in humans. Dig Liver Dis 2012; 44: 827-32.
115. Chiu PW, Wu JC, Teoh AY, et al. Peroral endoscopic myotomy for treatment of achalasia: from bench to bedside (with video). Gastrointest Endosc 2013; 77: 29-38.
116. Hungness ES, Teitelbaum EN, Santos BF, et al. Comparison of perioperative outcomes between peroral esophageal myotomy (POEM) and laparoscopic Heller myotomy. J Gastrointest Surg 2013; 17: 228-35.
117. Duranceau A, Liberman M, Martin J, et al. End-stage achalasia. Dis Esophagus 2012; 25: 319-30.
118. Eldaif SM, Mutrie CJ, Rutledge WC, et al. The risk ofesophageal resection after esophagomyotomy for achalasia. Ann Thorac Surg 2009; 87: 1558-62; discussion 62-63.
119. Molena D, Yang SC. Surgical management ofend-stage achalasia. Semin Thorac Cardiovasc Surg 2012; 24: 19-26.
120. Ghoshal UC, Kumar S, Saraswat VA, et al. Long-term follow-up after pneumatic dilation for achalasia cardia: factors associated with treatment failure and recurrence. Am J Gastroenterol 2004; 99: 2304-10.
121. Ghoshal UC, Rangan M. A review of factors predicting outcome of pneumatic dilation in patients with achalasia cardia. J Neurogastroenterol Motil 2011; 17: 9-13.
122. Chino O, Kijima H, Shimada H, et al. Clinicopathological studies ofesophageal carcinoma in achalasia: analyses of carcinogenesis using histological and immunohistochemical procedures. Anticancer Res 2000; 20: 3717-22.
123. Just-Viera JO, Haight C. Achalasia and carcinoma of the esophagus. Surg Gynecol Obstet 1969; 128: 1081-95.
124. Meijssen MA, Tilanus HW, van Blankenstein M, et al. Achalasia complicated by oesophageal squamous cell carcinoma: a prospective study in 195 patients. Gut 1992; 33: 155-58.
125. Streitz JM Jr, Ellis FH Jr, Gibb SP, et al. Achalasia and squamous cell carcinoma of the esophagus: analysis of 241 patients. Ann Thorac Surg 1995; 59: 1604-09.
126. Wychulis AR, Woolam GL, Andersen HA, et al. Achalasia and carcinoma of the esophagus. JAMA 1971; 215: 1638-41.
127. Dunaway PM, Wong RK. Risk and surveillance intervals for squamous cell carcinoma in achalasia. Gastrointest Endosc Clin N Am 2001; 11: 425-34, ix.
128. Zaninotto G, Rizzetto C, Zambon P, et al. Long-term outcome and risk of oesophageal cancer after surgery for achalasia. Br J Surg 2008; 95: 1488-94.
129. Leeuwenburgh I, Scholten P, Alderliesten J, et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol 2010; 105: 2144-49
130. Lehman MB, Clark SB, Ormsby AH, et al. Squamous mucosal alterations in esophagectomy specimens from patients with end-stage achalasia. Am J Surg Pathol 2001; 25: 1413-18.
131. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role ofendoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63: 570-80.
132. Boller D, Spieler P, Schoenegg R, et al. Lugol chromoendoscopy combined with brush cytology in patients at risk for esophageal squamous cell carcinoma. Surg Endosc 2009; 23: 2748-54.
133. Rohof WO, Bergman J, Bartelsman JF, et al. Screening for dysplasia in idiopathic achalasia using Lugol staining. Gastroenterology 2011; 140: S227.
134. Zendehdel K, Nyren O, Edberg A, et al. Risk ofesophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol 2011; 106: 57-61
135. Leeuwenburgh I, Gerrits MM, Capello A, et al. Expression of p53 as predictor for the development ofesophageal cancer in achalasia patients. Dis Esophagus 2010; 23: 506-11.
136. Vela MF, Richter JE, Wachsberger D, et al. Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection. Am J Gastroenterol 2004; 99: 1029-36.
137. Rohof WO, Hirsch DP, Kessing BF, et al. Efficacy of treatment for patients with achalasia depends on the distensibility of the esophagogastric junction. Gastroenterology 2012; 143: 328-35.
138. Kwiatek MA, Pandolfino JE, Hirano I, et al. Esophagogastric junction distensibility assessed with an endoscopic functional luminal imaging probe (EndoFLIP). Gastrointest Endosc 2010; 72: 272-78.
139. Savarino E, Gemignani L, Zentilin P, et al. Achalasia with dense eosinophilic infiltrate responds to steroid therapy. Clin Gastroenterol Hepatol 2011; 9: 1104-06.
140. Shaker A, Rubin DC. Stem cells: one step closer to gut repair. Nature 2012; 485: 181-82.
141. Metzger M, Caldwell C, Barlow AJ, et al. Enteric nervous system stem cells derived from human gut mucosa for the treatment of aganglionic gut disorders. Gastroenterology 2009; 136: 2214-25.
142. Sasselli V, Micci MA, Kahrig KM, et al. Evaluation of ES-derived neural progenitors as a potential source for cell replacement therapy in the gut. BMC Gastroenterol 2012; 12: 81.
143. Kulkarni S, Zou B, Hanson J, et al. Gut-derived factors promote neurogenesis of CNS-neural stem cells and nudge their differentiation to an enteric-like neuronal phenotype. Am J Physiol Gastrointest Liver Physiol 2011; 301: G644-55.